Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Theravance’s Persistence On Telavancin Rewarded With Positive Cmte. Vote

Executive Summary

FDA’s Anti-Infective Drugs Advisory Committee endorsed Vibativ for limited use in nosocomial pneumonia. The committee was convened at the recommendation of Office of New Drugs Director John Jenkins, who denied the company’s appeal of a second “complete response” letter but urged the NDA be re-evaluated.

Advertisement

Related Content

If At First You Don’t Succeed, Try Dispute Resolution
Theravance’s Vibativ Adds Long-Sought Pneumonia Indication
For Theravance, A Big Year Gets Off To A Strong Start
Mortality Vs. Clinical Cure: Telavancin Review Expected To Renew Debate On Nosocomial Pneumonia Endpoints
Maximizing PDUFA V Meeting Opportunities Requires Work By Sponsors
Theravance’s Vibativ To Get FDA Panel Review For Hospital-Acquired Pneumonia
Antibiotic Incentives: FDA’s Woodcock Says LPAD Could Be Better Than Exclusivity, But Questions Remain
Emerging Sponsors And FDA: Will Better Communication Under PDUFA V Ease Inherent Tensions?
Hospital-Acquired Pneumonia Is Life Or Death, FDA Says; Recommends Sole Primary Endpoint
Theravance Gets To Market With Vibativ, But HAP Indication Could Be Pushed To 2010

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS054930

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel